We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GILD Stock Down on Report of Cut in HIV Prevention Spending
Read MoreHide Full Article
Shares of Gilead Sciences, Inc. (GILD - Free Report) were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding for HIV prevention in the country.
GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio, Descovy and Truvada. Shares of another HIV drugmaker, GSK plc (GSK - Free Report) , were also down 2.08% on the news.
However, the direct impact of this reduction under the Trump administration on these drugmakers is likely to be minimal. The reduction in funding would primarily target a Centers for Disease Control and Prevention division that helps fund local health departments and nonprofits.
The report of a cut in the federal government funding for HIV prevention adds to investor anxiety about broader potential reductions to Medicaid, which could impact access to HIV drugs.
Gilead Sciences is looking to get another drug approved for HIV prevention – lenacapavir. The optimism regarding lenacapavir’s approval has boosted investor sentiment of late.
GILD’s shares have surged 17.2% year to date compared with the industry’s growth of 6.8%.
Image Source: Zacks Investment Research
GILD – A Major Player in the HIV Prevention Space
At present, there are two FDA-approved daily oral medications for pre-exposure prophylaxis (PrEP) — Truvada and Descovy. Descovy (FTC 200 mg/TAF 25 mg) for PrEP has witnessed good uptake. It maintains more than 40% market share in the PrEP market in the United States. Descovy for PrEP is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex.
Truvada is a two-drug combination of emtricitabine and tenofovir disoproxil fumarate, approved for the treatment of HIV-1 infection and PrEP.
The company is also looking to get FDA approval for lenacapavir for HIV prevention. Lenacapavir demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option.
Gilead Sciences’ application for the approval of lenacapavir is currently under review in both the United States and the European Union. The FDA has granted Priority Review to GILD’s NDA submissions for lenacapavir and set a target action date of June 19, 2025.
The strong results from the PURPOSE study increase the probability of lenacapavir’s approval, which should further solidify GILD’s HIV franchise. Lenacapavir has a competitive advantage as it needs to be taken only twice yearly, unlike daily oral pills, and addresses a broad population.
Approval of better HIV treatments should strengthen the HIV franchise in the wake of increasing competition from GSK.
A long-acting injectable form of PrEP was also approved by the FDA. In 2021, the regulatory body approved ViiV Healthcare’s Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms for PrEP to reduce the risk of sexually acquired HIV.
ViiV Healthcare is a global specialist HIV company, majorly owned by GSK with Pfizer (PFE - Free Report) and Shionogi as shareholders. The company was formed by GSK and Pfizer in 2009.
Apretude is given first as two initiation injections, administered a month apart and then every two months. Patients in need can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to understand how well they can tolerate the drug.
GSK posted 13% growth in HIV sales in 2024, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato.
Image: Shutterstock
GILD Stock Down on Report of Cut in HIV Prevention Spending
Shares of Gilead Sciences, Inc. (GILD - Free Report) were down 2.47% after the Wall Street Journal reported that The Health and Human Services Department is evaluating plans to slash the federal government funding for HIV prevention in the country.
GILD boasts a market-leading portfolio of HIV treatments both for treating the disease and prevention. The company has two drugs for HIV prevention in its portfolio, Descovy and Truvada. Shares of another HIV drugmaker, GSK plc (GSK - Free Report) , were also down 2.08% on the news.
However, the direct impact of this reduction under the Trump administration on these drugmakers is likely to be minimal. The reduction in funding would primarily target a Centers for Disease Control and Prevention division that helps fund local health departments and nonprofits.
The report of a cut in the federal government funding for HIV prevention adds to investor anxiety about broader potential reductions to Medicaid, which could impact access to HIV drugs.
Gilead Sciences is looking to get another drug approved for HIV prevention – lenacapavir. The optimism regarding lenacapavir’s approval has boosted investor sentiment of late.
GILD’s shares have surged 17.2% year to date compared with the industry’s growth of 6.8%.
Image Source: Zacks Investment Research
GILD – A Major Player in the HIV Prevention Space
At present, there are two FDA-approved daily oral medications for pre-exposure prophylaxis (PrEP) — Truvada and Descovy.
Descovy (FTC 200 mg/TAF 25 mg) for PrEP has witnessed good uptake. It maintains more than 40% market share in the PrEP market in the United States. Descovy for PrEP is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex.
Truvada is a two-drug combination of emtricitabine and tenofovir disoproxil fumarate, approved for the treatment of HIV-1 infection and PrEP.
The company is also looking to get FDA approval for lenacapavir for HIV prevention. Lenacapavir demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option.
Gilead Sciences’ application for the approval of lenacapavir is currently under review in both the United States and the European Union.
The FDA has granted Priority Review to GILD’s NDA submissions for lenacapavir and set a target action date of June 19, 2025.
The strong results from the PURPOSE study increase the probability of lenacapavir’s approval, which should further solidify GILD’s HIV franchise. Lenacapavir has a competitive advantage as it needs to be taken only twice yearly, unlike daily oral pills, and addresses a broad population.
Approval of better HIV treatments should strengthen the HIV franchise in the wake of increasing competition from GSK.
A long-acting injectable form of PrEP was also approved by the FDA. In 2021, the regulatory body approved ViiV Healthcare’s Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms for PrEP to reduce the risk of sexually acquired HIV.
ViiV Healthcare is a global specialist HIV company, majorly owned by GSK with Pfizer (PFE - Free Report) and Shionogi as shareholders.
The company was formed by GSK and Pfizer in 2009.
Apretude is given first as two initiation injections, administered a month apart and then every two months. Patients in need can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to understand how well they can tolerate the drug.
GSK posted 13% growth in HIV sales in 2024, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato.
GILD’s Zacks Rank
Gilead Sciences currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.